H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to neuroscience and the treatment of brain diseases. The company's core business encompasses the entire value chain from research and development to the manufacturing and global marketing of prescription medications. Lundbeck's product portfolio targets a range of central nervous system (CNS) disorders, including major depressive disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, and migraines. Key strategic brands driving its revenue include Rexulti, Brintellix/Trintellix, the Abilify LAI franchise, and Vyepti. The company operates through geographic segments covering Europe, the United States, and international markets, with research centers located in Denmark and the US. Founded in 1915, Lundbeck is majority-owned by the Lundbeck Foundation, which ensures long-term funding for scientific research while maintaining corporate control.
